• Oncology
  • Exited

Solasia Pharma K.K. expedites patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia has Asian rights to Sancuso® (extended release granisetron transdermal patch) from ProStrakan Group plc and an exclusive license to ZIOPHARM’s SP-02 / darinaparsin, in major Asian countries. Solasia is currently conducting a Phase 1 study of darinaparsin in PTCL in Japan and Korea.